KR20020086911A - 알츠하이머 질환과 관련된 신경정신적 행동의 치료를 위한갈란타민의 용도 - Google Patents

알츠하이머 질환과 관련된 신경정신적 행동의 치료를 위한갈란타민의 용도 Download PDF

Info

Publication number
KR20020086911A
KR20020086911A KR1020027011063A KR20027011063A KR20020086911A KR 20020086911 A KR20020086911 A KR 20020086911A KR 1020027011063 A KR1020027011063 A KR 1020027011063A KR 20027011063 A KR20027011063 A KR 20027011063A KR 20020086911 A KR20020086911 A KR 20020086911A
Authority
KR
South Korea
Prior art keywords
day
galantamine
weeks
dose
treatment
Prior art date
Application number
KR1020027011063A
Other languages
English (en)
Korean (ko)
Inventor
파리스윔루이스줄리엔
폰테코르보마이클
Original Assignee
얀센 파마슈티카 엔.브이.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 얀센 파마슈티카 엔.브이. filed Critical 얀센 파마슈티카 엔.브이.
Publication of KR20020086911A publication Critical patent/KR20020086911A/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
KR1020027011063A 2000-04-03 2001-03-28 알츠하이머 질환과 관련된 신경정신적 행동의 치료를 위한갈란타민의 용도 KR20020086911A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US19425900P 2000-04-03 2000-04-03
US60/194.259 2000-04-03
PCT/EP2001/003553 WO2001074339A2 (fr) 2000-04-03 2001-03-28 Utilisation de la galantamine dans le traitement du comportement neuropsychiatrique associe a la maladie d'alzheimer

Publications (1)

Publication Number Publication Date
KR20020086911A true KR20020086911A (ko) 2002-11-20

Family

ID=22716898

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020027011063A KR20020086911A (ko) 2000-04-03 2001-03-28 알츠하이머 질환과 관련된 신경정신적 행동의 치료를 위한갈란타민의 용도

Country Status (20)

Country Link
EP (1) EP1272192A2 (fr)
JP (1) JP2003528913A (fr)
KR (1) KR20020086911A (fr)
CN (1) CN1430514A (fr)
AU (2) AU2001265844B2 (fr)
BG (1) BG107093A (fr)
BR (1) BR0109770A (fr)
CA (1) CA2310926C (fr)
CZ (1) CZ20023543A3 (fr)
EE (1) EE200200554A (fr)
HR (1) HRP20020778A2 (fr)
HU (1) HUP0300566A3 (fr)
IL (1) IL152061A0 (fr)
MX (1) MXPA02009777A (fr)
NO (1) NO20024746L (fr)
PL (1) PL361272A1 (fr)
RU (1) RU2002129298A (fr)
SK (1) SK15422002A3 (fr)
WO (1) WO2001074339A2 (fr)
ZA (1) ZA200207935B (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6617361B2 (en) * 1999-11-05 2003-09-09 Be Able, Llc Behavior chemotherapy
ES2293287T3 (es) * 2003-07-25 2008-03-16 F. Hoffmann-La Roche Ag Combinacion de antagonista de mglur2 y de inhibidor de ache para el tratamiento de trastornos neurologicos agudos y/o cronicos.
DE10338544B4 (de) * 2003-08-19 2017-08-31 Janssen Pharmaceutica N.V. Buccale Formulierungen des Galanthamins und deren Anwendungen
JP5647099B2 (ja) 2008-03-27 2014-12-24 チェイス・ファーマスーティカルズ・コーポレーション 認知症を治療するための使用及び組成物
WO2013160728A1 (fr) 2012-04-26 2013-10-31 Alma Mater Studiorum - Universita' Di Bologna Composés à double ciblage pour le traitement de la maladie d'alzheimer
BG66818B1 (bg) * 2013-03-07 2019-01-31 Berbee Beheer B. V. Състав на екстракт от hippeastrum papilio за производство на лекарствени средства и хранителни добавки
WO2016187339A1 (fr) * 2015-05-18 2016-11-24 Synaptec Development Llc Clairance de galantamine d'amyloides
WO2023036105A1 (fr) * 2021-09-09 2023-03-16 上海日馨医药科技股份有限公司 Méthode de traitement d'une maladie neurodégénérative

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4663318A (en) * 1986-01-15 1987-05-05 Bonnie Davis Method of treating Alzheimer's disease
DE19509663A1 (de) * 1995-03-17 1996-09-19 Lohmann Therapie Syst Lts Verfahren zur Isolierung von Galanthamin
GB9600080D0 (en) * 1996-01-04 1996-03-06 Chiroscience Ltd Resolution process
US7939522B1 (en) 1998-11-23 2011-05-10 Bonnie M Davis Dosage formulations for acetylcholinesterase inhibitors
AU775914B2 (en) * 1998-12-24 2004-08-19 Janssen Pharmaceutica N.V. Controlled release galantamine composition
CA2310950C (fr) * 2000-04-03 2005-11-08 Janssen Pharmaceutica N.V. Posologie de galantamine efficace qui reduit les effets secondaires
CA2310990A1 (fr) * 2000-04-03 2000-10-09 Michael Pontecorvo Utilisation de la galantamine pour le traitement de la maladie d'alzheimer; ciblage de la cause sous-jacente de la maladie

Also Published As

Publication number Publication date
ZA200207935B (en) 2004-01-30
EP1272192A2 (fr) 2003-01-08
NO20024746L (no) 2002-11-28
MXPA02009777A (es) 2003-03-27
WO2001074339A2 (fr) 2001-10-11
WO2001074339A3 (fr) 2002-09-12
RU2002129298A (ru) 2004-03-27
AU2001265844B2 (en) 2005-04-14
CN1430514A (zh) 2003-07-16
HRP20020778A2 (en) 2004-04-30
PL361272A1 (en) 2004-10-04
NO20024746D0 (no) 2002-10-02
SK15422002A3 (sk) 2003-04-01
HUP0300566A3 (en) 2004-10-28
BR0109770A (pt) 2003-02-04
BG107093A (bg) 2003-06-30
JP2003528913A (ja) 2003-09-30
CA2310926C (fr) 2002-10-15
IL152061A0 (en) 2003-05-29
EE200200554A (et) 2004-04-15
CZ20023543A3 (cs) 2003-03-12
CA2310926A1 (fr) 2000-10-04
AU6584401A (en) 2001-10-15
HUP0300566A2 (hu) 2003-06-28

Similar Documents

Publication Publication Date Title
Kuna et al. Efficacy and safety of bilastine 20 mg compared with cetirizine 10 mg and placebo for the symptomatic treatment of seasonal allergic rhinitis: a randomized, double‐blind, parallel‐group study
Malykh et al. Piracetam and piracetam-like drugs
Tancer et al. The subjective effects of MDMA and mCPP in moderate MDMA users
Amass et al. Efficacy of daily and alternate-day dosing regimens with the combination buprenorphine–naloxone tablet
CA2310950C (fr) Posologie de galantamine efficace qui reduit les effets secondaires
TW202110450A (zh) 使用布魯頓酪胺酸激酶抑制劑治療慢性自發性蕁麻疹之方法
Casey et al. Sulpiride in tardive dyskinesia
KR20020086911A (ko) 알츠하이머 질환과 관련된 신경정신적 행동의 치료를 위한갈란타민의 용도
JPH0667842B2 (ja) 基本的うつ病を軽減するためのうつ病治療剤
JPH0920666A (ja) 成熟遅延および類似疾患の治療用医薬組成物
Amore et al. Long-term treatment of geropsychiatric depressed patients with venlafaxine
US20120010242A1 (en) Low dose pipamperone in treating mood disorders
AU2001265844A1 (en) A use of galantamine for the treatment of neuropsychiatric behaviour associated with alzheimer's disease
CN109069466A (zh) 5-ht6受体拮抗剂用于治疗阿尔茨海默病伴情感淡漠共病
Dupont et al. Oxatomide in the treatment of pruritus senilis: a double-blind placebo-controlled trial
Rouillon et al. Sulpiride in the treatment of somatoform disorders: results of a European observational study to characterize the responder profile
US20060172993A1 (en) Use of galantamine for the treatment of neuropsychiatric behaviour associated with Alzheimer's disease
Van Bijsterveld et al. Nedocromil sodium treats symptoms of perennial allergic conjunctivitis not fully controlled by sodium cromoglycate A double-masked placebo controlled group comparative study
Marazziti Venlafaxine treatment of obsessive-compulsive disorder
Bullock et al. Risperidone in the treatment of psychoses in the elderly: a case report series
WO2014128882A1 (fr) Agent thérapeutique pour la dépression anxieuse
Bennie et al. Comparison of trazodone and mianserin in depressive illness
Panas et al. Belladonna alkaloids and phenobarbital use in the treatment of irritable bowel syndrome: a review
Gerlach Pharmacology and clinical properties of selective dopamine antagonists with focus on substituted benzamides
Pitt et al. A Review of the Use of Donepezil in the Treatment of Alzheimer’s Disease

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E601 Decision to refuse application